公开(公告)号：US12139713B2

公开(公告)日：2024-11-12

申请号：US18407780

申请日：2024-01-09

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00 ,  C12Q1/68

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.

公开(公告)号：US12006502B2

公开(公告)日：2024-06-11

申请号：US18407815

申请日：2024-01-09

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00 ,  C12Q1/68

CPC classification number: C12N15/1138 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/531

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a fibrotic cell.

公开(公告)号：US20190216947A1

公开(公告)日：2019-07-18

申请号：US16247937

申请日：2019-01-15

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Gi Hoon NAM ,  Eun Jung Lee ,  Yoo Soo Yang ,  Cherl Hyun Jeong ,  In-San Kim ,  Kwangmeyung Kim

IPC: A61K47/69 ,  B82Y5/00 ,  C07K16/28 ,  B82Y40/00 ,  A61K31/704 ,  A61P35/00 ,  C07K14/785 ,  C07K14/79 ,  C07K14/705 ,  C07K14/005 ,  A61K31/337

CPC classification number: A61K47/6929 ,  A61K9/51 ,  A61K31/337 ,  A61K31/69 ,  A61K31/704 ,  A61K39/395 ,  A61P35/00 ,  B82Y5/00 ,  B82Y40/00 ,  C07K14/005 ,  C07K14/47 ,  C07K14/70546 ,  C07K14/785 ,  C07K14/79 ,  C07K16/2818

Abstract: The present invention relates to a novel recombinant nanocage and use thereof wherein the nanocage is formed by self-assembly of a fusion protein including a phagocytosis enhancing protein and a self-assembling protein, and to a protein nanocage complex in which an immunogenic cell death inducer is loaded in the nanocage as an active ingredient.

公开(公告)号：US20240325550A1

公开(公告)日：2024-10-03

申请号：US18618258

申请日：2024-03-27

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: A61K47/64 ,  A61P35/00 ,  C12N15/113

CPC classification number: A61K47/64 ,  A61P35/00 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/141

Abstract: Therapeutic compounds for inhibiting and reducing the expression of cell surface proteins and methods for treating cancer, inflammation, and diabetes using the therapeutic compounds.

公开(公告)号：US10905774B2

公开(公告)日：2021-02-02

申请号：US16247937

申请日：2019-01-15

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Gi Hoon Nam ,  Eun Jung Lee ,  Yoo Soo Yang ,  Cherl Hyun Jeong ,  In-San Kim ,  Kwangmeyung Kim

IPC: A61K39/00 ,  A61K47/00 ,  A61K9/14 ,  A61K39/12 ,  A61K47/69 ,  A61K31/704 ,  C07K14/79 ,  C07K14/47 ,  A61K31/69 ,  A61K9/51 ,  A61K39/395 ,  A61P35/00 ,  A61K31/337 ,  B82Y5/00 ,  B82Y40/00 ,  C07K14/005 ,  C07K14/705 ,  C07K14/785 ,  C07K16/28

Abstract: The present invention relates to a novel recombinant nanocage and use thereof wherein the nanocage is formed by self-assembly of a fusion protein including a phagocytosis enhancing protein and a self-assembling protein, and to a protein nanocage complex in which an immunogenic cell death inducer is loaded in the nanocage as an active ingredient.

公开(公告)号：US10781238B2

公开(公告)日：2020-09-22

申请号：US15756988

申请日：2016-09-02

Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION ,  KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： So Youn Kim ,  Gwang-Seob Kim ,  Jun Young Seo ,  In-San Kim

IPC: A61K47/65 ,  A61K47/64 ,  A61K38/17 ,  A61K49/00 ,  C07K14/47 ,  C07K14/79 ,  C07K19/00 ,  C07K14/435 ,  A61K38/00

Abstract: Disclosed are a human-derived ferritin monomer fragment and a fusion polypeptide using the same, and more particularly, to a human-derived ferritin of which a portion of a fourth loop and a fifth helix of the ferritin monomer fragment are removed, and a fusion polypeptide in which a polypeptide or a protein is fused to an N-terminus or a C-terminus of the ferritin monomer fragment.

公开(公告)号：US20190307794A1

公开(公告)日：2019-10-10

申请号：US16379523

申请日：2019-04-09

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Yeon-Sun HONG ,  Hyo Suk Kim ,  Yoo Soo Yang ,  Sun Hwa Kim ,  In-San Kim ,  Ick Chan Kwon

IPC: A61K35/15 ,  C12N5/0786 ,  C12N5/0784 ,  C12N5/0775 ,  A61K9/127 ,  C12N5/00

Abstract: The present invention relates to a method of inducing trans-differentiating a first type of immune cell into a second type of immune cell comprising: isolating exosomes from the second type of immune cell that has undergone differentiation, and treating the first type of immune cell or a cell population including the first type of immune cell with the isolated exosomes in vitro.

公开(公告)号：US20240191237A1

公开(公告)日：2024-06-13

申请号：US18407780

申请日：2024-01-09

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00

CPC classification number: C12N15/1138 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/531

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.

公开(公告)号：US20240043846A1

公开(公告)日：2024-02-08

申请号：US18057050

申请日：2022-11-18

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00

CPC classification number: C12N15/1138 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/531

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

公开(公告)号：US11319360B2

公开(公告)日：2022-05-03

申请号：US16475052

申请日：2017-12-29

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Eun-ee Koh ,  Eun Jung Lee ,  Yoo Soo Yang ,  In-San Kim

IPC: C07K14/71 ,  A61P35/00 ,  C12N9/12 ,  A61K38/00

Abstract: The present invention provides a recombinant exosome and uses thereof. More particularly, the present invention provides a recombinant exosome wherein a phagocytosis promoting protein is presented on the surface thereof.